A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Genentech, Inc.
OncoC4, Inc.
USWM, LLC (dba US WorldMeds)
Sotio Biotech Inc.
ViroMissile, Inc.
Tizona Therapeutics, Inc
MacroGenics
Conjupro Biotherapeutics, Inc.
Innate Pharma
M.D. Anderson Cancer Center
Amgen
HiFiBiO Therapeutics
HiFiBiO Therapeutics
Actym Therapeutics, Inc.
Pfizer
Arcus Biosciences, Inc.
Toray Industries, Inc
University of Virginia
Columbia University
Seagen Inc.
Vincerx Pharma, Inc.
Inhibrx Biosciences, Inc
NGM Biopharmaceuticals, Inc
Xencor, Inc.
ADC Therapeutics S.A.
DNAtrix, Inc.
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
BioEclipse Therapeutics
Adaptimmune
University of Florida
Fate Therapeutics
Fate Therapeutics
Xencor, Inc.
Quadriga Biosciences, Inc.
Genzada Pharmaceuticals USA, Inc.
Xencor, Inc.
AbbVie
Pfizer
AbbVie
Fate Therapeutics
Incyte Corporation
Incyte Corporation
Seagen Inc.
KitovPharma
Abramson Cancer Center at Penn Medicine
Santa Maria Biotherapeutics
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Rutgers, The State University of New Jersey